FDA CDER director Patrizia Cavazzoni announces resignation
The US Food and Drugs Administration (FDA) has confirmed that its director of the Centre for Drug Evaluation and Research…
10 Jan 2025
Alzheimer’s total prevalent cases to reach 22.51 million in 8MM in 2033
Estimates by data analytics company GlobalData suggest that the total prevalent cases of Alzheimer’s disease (according to the DSM-IV criteria) will increase at an annual growth rate (AGR) of 4.08%…
10 Jan 2025
Climb Bio enters licensing deal with Mabworks for CLYM116 development
Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising the anti-A proliferation-inducing ligand (APRIL) monoclonal antibody, CLYM116 (formerly MIL116), outside Greater China. Under…
10 Jan 2025
A2 Biotherapeutics raises $80m to advance CAR-T therapies for solid tumours
US-based biotech company A2 Biotherapeutics (A2 Bio) has secured $80m in funding to advance its pipeline of chimeric antigen receptor (CAR)-T cell therapies for solid tumour cancers. The Series C…
10 Jan 2025
Light Horse emerges with $62m and Novartis partnership worth up to $1bn
Light Horse Therapeutics has galloped on to the biotech scene with $62m in Series A financing and a multi-target collaboration with Novartis that will see the big pharma company use…
10 Jan 2025
Coave Therapeutics raises $33m in funding to advance ALIGATER platform
Coave Therapeutics has raised €32m ($33m) in a Series A financing round for advancing its Advanced Vectors-Ligand Conjugates (ALIGATER) platform. This platform claims to address the limitations in genetic payloads…
10 Jan 2025
Newron and Myung In Pharm sign agreement for evenamide development
Newron Pharmaceuticals and Myung In Pharm have signed a licence agreement to develop, manufacture, and commercialise the former’s glutamate modulator, evenamide, for schizophrenia in South Korea. Evenamide is an add-on…